Immuno-oncology drugs Keytruda (pembrolizumab, Merck & Co. Inc.) and Opdivo (nivolumab, Bristol-Myers Squibb Co.) came in first and third in the latest edition of the Trinity Drug Index, with hepatitis C drug Harvoni (sofosbuvir/ledipasvir, Gilead Sciences Inc.) taking the second spot. This version of the annual index scores the 41 drugs approved by the FDA in 2014 based on commercial, therapeutic and R&D categories.